La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Viking Therapeutics Croissance future

Future contrôle des critères 2/6

Viking Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 2.3% et de 74% par an respectivement. Le BPA devrait croître de de 5.9% par an. Le rendement des capitaux propres devrait être -21.4% dans 3 ans.

Informations clés

2.3%

Taux de croissance des bénéfices

5.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	74.0%
Rendement futur des capitaux propres	-21.4%
Couverture par les analystes	Good
Dernière mise à jour	25 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:VKTX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	39	-201	-219	-271	9
12/31/2025	3	-176	-170	-197	10
12/31/2024	N/A	-110	-103	-90	11
6/30/2024	N/A	-97	-72	-72	N/A
3/31/2024	N/A	-94	-55	-55	N/A
12/31/2023	N/A	-86	-73	-73	N/A
9/30/2023	N/A	-81	-67	-67	N/A
6/30/2023	N/A	-74	-61	-61	N/A
3/31/2023	N/A	-72	-63	-63	N/A
12/31/2022	N/A	-69	-48	-48	N/A
9/30/2022	N/A	-62	-50	-50	N/A
6/30/2022	N/A	-59	-47	-47	N/A
3/31/2022	N/A	-57	-47	-47	N/A
12/31/2021	N/A	-55	-48	-48	N/A
9/30/2021	N/A	-54	-41	-41	N/A
6/30/2021	N/A	-50	-35	-35	N/A
3/31/2021	N/A	-44	-28	-28	N/A
12/31/2020	N/A	-39	-22	-22	N/A
9/30/2020	N/A	-36	-28	-28	N/A
6/30/2020	N/A	-32	-26	-26	N/A
3/31/2020	N/A	-31	-26	-26	N/A
12/31/2019	N/A	-26	-25	-25	N/A
9/30/2019	N/A	-24	-16	-16	N/A
6/30/2019	N/A	-24	-18	-18	N/A
3/31/2019	N/A	-23	-17	-17	N/A
12/31/2018	N/A	-22	-19	-19	N/A
9/30/2018	N/A	-21	-20	-20	N/A
6/30/2018	N/A	-20	-18	-18	N/A
3/31/2018	N/A	-19	N/A	-17	N/A
12/31/2017	N/A	-21	N/A	-15	N/A
9/30/2017	N/A	-20	N/A	-13	N/A
6/30/2017	N/A	-18	N/A	-13	N/A
3/31/2017	N/A	-16	N/A	-12	N/A
12/31/2016	N/A	-15	N/A	-11	N/A
9/30/2016	N/A	-16	N/A	-12	N/A
6/30/2016	N/A	-17	N/A	-13	N/A
3/31/2016	N/A	-21	N/A	-11	N/A
12/31/2015	N/A	-23	N/A	-9	N/A
9/30/2015	N/A	-17	N/A	-6	N/A
6/30/2015	N/A	-12	N/A	-3	N/A
3/31/2015	N/A	-27	N/A	-2	N/A
12/31/2014	N/A	-22	N/A	-2	N/A
9/30/2014	N/A	-23	N/A	-1	N/A
6/30/2014	N/A	-23	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: VKTX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: VKTX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: VKTX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de VKTX ( 74% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de VKTX ( 74% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: VKTX devrait être non rentable dans 3 ans.

Viking Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 14% to US$108

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

Price target increased by 9.1% to US$36.33

Price target increased by 7.5% to US$31.50

Price target increased by 12% to US$30.80

Recent updates

Independent Director exercised options and sold US$1.0m worth of stock

President recently sold US$6.7m worth of stock

President notifies of intention to sell stock

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Viking Therapeutics, Inc. to Report Q2, 2024 Results on Jul 24, 2024

Viking Therapeutics, Inc. Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists At 84th Scientific Sessions of the American Diabetes Association

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2B Voyage Study of Vk2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (Nash)

New major risk - Revenue and earnings growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics, Inc. to Report Q1, 2024 Results on Apr 24, 2024

Viking Therapeutics, Inc., Annual General Meeting, May 21, 2024

Viking Therapeutics: Future Weight Loss Heavyweight?

Price target increased by 14% to US$108

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Viking Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $550.035 million.

Viking Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Share price stability

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

President notifies of intention to sell stock

Price target increased by 9.1% to US$36.33

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. to Report Q4, 2023 Results on Feb 07, 2024

President notifies of intention to sell stock

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Chief Financial Officer recently sold US$269k worth of stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Viking Therapeutics, Inc. Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2023

Viking Therapeutics, Inc. to Report Q3, 2023 Results on Oct 25, 2023

Viking Therapeutics, Inc. Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Oral Presentation At Obesityweek 2023

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Announces Initiation of Phase 2 Venture Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Patients with Obesity

Viking Therapeutics, Inc. to Report Q2, 2023 Results on Jul 26, 2023

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 7.5% to US$31.50

Ligand's Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of Voyage Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Price target increased by 12% to US$30.80

Price target increased by 8.1% to US$29.30

Price target increased by 15% to US$21.80

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Provides an Update on Its Clinical Pipeline and Other Corporate Developments

Viking Therapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Insufficient new directors

Price target decreased to US$17.33

Viking Therapeutics, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Viking Therapeutics: Playing Second Fiddle To Madrigal

Insufficient new directors

Viking Therapeutics, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Viking Therapeutics Announces FDA Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 2000 Dynamic Index

Director recently bought US$111k worth of stock

Viking Therapeutics, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Revisiting Viking Therapeutics

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics, Inc., Annual General Meeting, May 24, 2022

Viking Therapeutics, Inc. to Report Q4, 2021 Results on Feb 09, 2022

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

Price target increased to US$20.67

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 3000E Growth Index

Viking Therapeutics, Inc. Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Director recently bought US$114k worth of stock